+66.7%
SNXX vs MRNA
+437.3%
-370.6%
-88.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -15.7% | +13.1% | -28.9% | -15.7% |
| 7D | -47.8% | +20.6% | -68.4% | -47.7% |
| 30D | -66.0% | +27.1% | -93.2% | -65.9% |
| 3M | -57.5% | +353.4% | -410.9% | -57.4% |
| 6M | -66.7% | +446.3% | -513.0% | -72.2% |
| All | +66.7% | +437.3% | -370.6% | +81.9% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling